ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1046
0,00%
Bitcoin
67.092,67
0,23%
Brent Oil
83,76
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Nurix Therapeutics Inc (NRIX)

  7. Nurix Therapeutics Inc (NRIX) Notícias

NRIX

Nurix Therapeutics (NRIX)

Nurix Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NRIX
DataHoraFonteTítuloCódigoCompanhia
14/05/202411:00GlobeNewswire Inc.Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)NASDAQ:NRIXNurix Therapeutics Inc
07/05/202408:00GlobeNewswire Inc.Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare ConferenceNASDAQ:NRIXNurix Therapeutics Inc
16/04/202419:21GlobeNewswire Inc.Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:NRIXNurix Therapeutics Inc
12/04/202400:38GlobeNewswire Inc.Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public OfferingNASDAQ:NRIXNurix Therapeutics Inc
11/04/202417:00GlobeNewswire Inc.Nurix Therapeutics Announces Proposed Public OfferingNASDAQ:NRIXNurix Therapeutics Inc
10/04/202408:00GlobeNewswire Inc.Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate UpdateNASDAQ:NRIXNurix Therapeutics Inc
09/04/202414:15GlobeNewswire Inc.Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell MalignanciesNASDAQ:NRIXNurix Therapeutics Inc
09/04/202408:00GlobeNewswire Inc.Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6NASDAQ:NRIXNurix Therapeutics Inc
03/04/202408:00GlobeNewswire Inc.Nurix Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:NRIXNurix Therapeutics Inc
02/04/202408:00GlobeNewswire Inc.Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead SciencesNASDAQ:NRIXNurix Therapeutics Inc
25/03/202408:00GlobeNewswire Inc.Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)NASDAQ:NRIXNurix Therapeutics Inc
20/03/202410:40GlobeNewswire Inc.Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) MeetingNASDAQ:NRIXNurix Therapeutics Inc
11/03/202408:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRIXNurix Therapeutics Inc
11/03/202408:00GlobeNewswire Inc.Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 TrialNASDAQ:NRIXNurix Therapeutics Inc
05/03/202418:30GlobeNewswire Inc.Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual MeetingNASDAQ:NRIXNurix Therapeutics Inc
16/02/202421:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
16/02/202418:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NRIXNurix Therapeutics Inc
15/02/202418:51Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NRIXNurix Therapeutics Inc
15/02/202418:00GlobeNewswire Inc.Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate UpdateNASDAQ:NRIXNurix Therapeutics Inc
14/02/202410:51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NRIXNurix Therapeutics Inc
01/02/202418:01GlobeNewswire Inc.Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 DegraderNASDAQ:NRIXNurix Therapeutics Inc
29/01/202418:00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NRIXNurix Therapeutics Inc
16/01/202418:48Dow Jones NewsNurix Therapeutics Gets FDA Fast-Track Designation for NX-5948NASDAQ:NRIXNurix Therapeutics Inc
16/01/202418:01GlobeNewswire Inc.Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLLNASDAQ:NRIXNurix Therapeutics Inc
08/01/202409:00GlobeNewswire Inc.Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune DiseasesNASDAQ:NRIXNurix Therapeutics Inc
02/01/202418:01GlobeNewswire Inc.Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:NRIXNurix Therapeutics Inc
13/12/202318:32GlobeNewswire Inc.Judith A. Reinsdorf and Katherine M. Sandstrom Named to Toll Brothers Board of DirectorsNASDAQ:NRIXNurix Therapeutics Inc
11/12/202314:00GlobeNewswire Inc.Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual MeetingNASDAQ:NRIXNurix Therapeutics Inc
04/12/202318:01GlobeNewswire Inc.Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual MeetingNASDAQ:NRIXNurix Therapeutics Inc
07/11/202318:01GlobeNewswire Inc.Nurix Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:NRIXNurix Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:NRIX

Seu Histórico Recente

KUCN
DEXEETH
Dexe
LSE
RYA
Ryanair
NYSE
RMPL-
RiverNorth Capital and I...
BIT
UB261N
UniCredit Bank
BIT
P1YIW8
NLBNPIT1YIW8 20991231 19...
COIN
BUMBAGBP
NASDAQ
IBLUU
Blue Room Acquisition
BIT
P1V9C3
NLBNPIT1V9C3 20991231 15...
NASDAQ
SOXX
iShares Semiconductor ETF
UNSW3
SYMMETH
Symmetric
TSXV
VANC
NASDAQ
BTFX
Valkyrie Bitcoin Futures...
ASX
BXBKOU
BIT
P1TSW7
NLBNPIT1TSW7 20240620 4800
GATE
SOLRUSDT
SolRazr
BIT
P1UQB3
NLBNPIT1UQB3 20991231 5....
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados